Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Eli Lilly and Company 10-Q filed Oct 30, 2025
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 7, 2025: 2 added · 1 removed · 21 modified; 11 with only figures updated; 3 moved without change
-
Modified · Financial Results
Revenue increased for the three and
sixnine months endedJuneSeptember 30, 2025, driven by increased volume, partially offset by lower realized prices. The increased volume and lower realized prices during the three andsixnine months endedJuneSeptember 30, 2025 were primarily driven byZepboundMounjaro andMounjaroZepbound.